Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped company decision

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Uveal Melanoma

Interventions

BIOLOGICAL: BPX-701
DRUG: Rimiducid

Sponsor

Bellicum Pharmaceuticals